BMS' Opdivo Heading Towards Indian Debut?
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) appears to be on course to a potential Indian debut, after a key local expert panel recommended the product for marketing.